92765-7

Adalimumab neutralizing antibody [Titer] in Serum by Bioassay

Active

Term Description

The result of this assay represents the minimum serum dilution at which adalimumab activity is no longer blocked by anti-adalimumab antibody in the patient specimen (i.e., the dilution at which the antibody's neutralizing effect is eliminated). The term is created for an anti-adalimumab antibody assay employing the cell-based iLite TNF-alpha detection kit, but the term is not restricted in use to that product.

Part Descriptions

LP173592-9 Adalimumab
Adalimumab is a human monoclonal antibody that binds tumor necrosis factor alpha (TNFα). TNFα is a cell signaling protein that, when present in excess, may lead to the development of inflammatory immune diseases including Crohn's disease, rheumatoid arthritis, psoriatic arthritis and inflammatory bowel disease. Adalimumab inactivates TNFα by binding to the TNFα receptor. PMID: 23943614 Treatment with adalimumab does not necessitate laboratory monitoring though association with increased transamines and pancytopenia may argue for intermittant blood cell counts and liver function tests. Adalimumab has been associated with serious infections including the reactivation of tuberculosis and deep fungal infections as well as other rare side effects, including lymphoma, heart failure and demyelinating disease. PMID: 16011443 Source: Regenstrief LOINC

LP207365-0 Ab.Neut
Neutralizing antibodies are antibodies that interfere with the interaction between the virus and its host cell receptor, therefore preventing infectivity. Neutralizing antibodies can be detected using a traditional VNT or other methods such as pseudovirus VNT and surrogate VNT. VNT and pseudovirus VNT use live virus (the actual virus or a recombinant virus that incorporates the viral antigen of interest, respectively) and cell culture to assess the virus-host interaction and whether neutralizing antibodies are present that block that interaction. Surrogate VNT (sVNT) does not use live virus but rather uses purified viral antigen and host cell receptor protein to mimic the same interaction. The sVNT method is currently (2021) represented in LOINC as IA, because it is an immunoassay-based method. Source: Regenstrief LOINC

LP310465-2 Adalimumab Ab.Neut
Antibodies to adalimumab were shown to develop in 67% of patients within the first 28 weeks of treatment. Only thirteen percent of patients with adalimumab antibodies experienced relief from symptoms compared to 48% of patients without antibodies to adalimumab. Only 4% of patients with antibodies went into remission compared to 34% of patients who achieved remission without anti-adalimumab antibodies. Antibodies to adalimumab reduced the likelihood that patients would have relief from disease symptoms or go into remission. PMID: 21486979 Source: Regenstrief LOINC

LOINC Names Get Info

Fully-Specified Name: Adalimumab Ab.Neut:Titr:Pt:Ser:SemiQn:Bioassay
Long Common Name: Adalimumab neutralizing antibody [Titer] in Serum by Bioassay
Short Name: Adalimumab NAb Titr Ser Bioassay
Display Name: Adalimumab neut ab Bioassay (S) [Titer]
Consumer Name Alpha Get Info: Adalimumab neutralizing antibody, Blood

Part Model Get Info

Component
Adalimumab Ab.Neut
LP310465-2
- Analyte
  Adalimumab Ab.Neut
  LP310465-2
  - Component Numerator
    Adalimumab Ab.Neut
    LP310465-2
    - Component Numerator Core
      Adalimumab
      LP173592-9
    - Component Numerator Core Suffix
      Ab.Neut
      LP207365-0
  - Component Denominator
    NULL
    - Component Denominator Core
      NULL
    - Component Denominator Core Suffix
      NULL
- Challenge
  NULL
- Adjustment
  NULL
- Count
  NULL
Property
Titr
LP6881-9
Time
Pt
LP6960-1
- Time Core
  Pt
  LP6960-1
- Time Modifier
  NULL
System
Ser
LP7567-3
- System Core
  Ser
  LP7567-3
- Super System
  NULL
Scale
SemiQn
LP436123-6
Method
Bioassay
LP6150-9

Basic Attributes

Class: SERO
Type: Laboratory
First Released: Version 2.66
Last Updated: Version 2.75 (MAJ)
Order vs. Observation: Both

Language Variants Get Info

Tag	Language	Translation
cs-CZ	Czech (Czechia)	Adalimumab Ab.neutralizační:Arbitrární koncentrace (titr):Časový bod:Sérum:Semikvantitativní:Biologický test
el-GR	Greek (Greece)	Αδαλιμουμάμπη Ab.Neut:Titr:Pt:Ορός:Ημιποσοτική:Βιοδοκιμασία Synonyms: Ab.Neut Pt SERO Titr Αδαλιμουμάμπη Αντίσωμα Βιοδοκιμασία Ημιποσοτική Ορός
es-ES	Spanish (Spain)	Adalimumab Anticuerpos antineutrófilos:Titulo / Factor de dilución:Punto temporal:Suero:Semicuantitativo:Bioensayo Synonyms: Semicuantitativo
es-MX	Spanish (Mexico)	Adalimumab Ab.Neut:Título:Punto temporal:Suero:Cuantitativo:Bioensayo
fr-FR	French (France)	Adalimumab Ac neutralisant:Titre:Ponctuel:Sérum:Semi-Quantitatif:Bio-essai
it-IT	Italian (Italy)	Adalimumab Ab.Neut:Titr:Pt:Siero:SemiQn:Saggio biologico Synonyms: anticorpo Punto nel tempo (episodio) Siero Sierologia (anticorpi e la maggior parte degli ant Titolo
nl-NL	Dutch (Netherlands)	adalimumab As.neutraliserend:titer:moment:serum:semikwantitatief:bioassay Synonyms: antistof; antilichaam
pl-PL	Polish (Poland)	Adalimumab Ab.Neutralizujące:miano:punkt w czasie:surowica:półilościowy:test biologiczny Synonyms: Przeciwciała do adalimumabu Przeciwciała neutralizujące do adalimumabu
zh-CN	Chinese (China)	阿达木单抗抗体.中和:滴定度:时间点:血清:半定量型:生物鉴定 Synonyms: Ab;自身抗体 Adalimumab 单抗;人体抗肿瘤坏死因子-α单克隆抗体;阿达莫单抗;阿达木;阿达莫;阿达木单克隆抗体中和试验;中和抗体;中和效价;滴定浓度;滴定率;滴定量;滴度;稀释倍数;稀释因子;稀释系数时刻;随机;随意;瞬间生物检定;生物检验;生物测定;生物测试血清;血清学;血清学检验项目;血清学检验项目 (非微生物学);血清学检验项目（非微生物学）;血清学检验项目类;血清学检验项目类 (非微生物学);血清学类;血清学类检验项目;血清学类检验项目 (非微生物学);血清学类试验;血清学类试验 (非微生物学);血清学试验;血清学试验 (非微生物学);血清学试验（非微生物学）;血清学试验类 (非微生物学);血清类

Example Units

Unit	Source
{titer}	Example UCUM Units

LOINC Terminology Service (API) using HL7^® FHIR^® Get Info

CodeSystem lookup: https://fhir.loinc.org/CodeSystem/$lookup?system=http://loinc.org&code=92765-7

LOINC Copyright

Copyright © Regenstrief Institute, Inc. All Rights Reserved. To the extent included herein, the LOINC table and LOINC codes are copyright © Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. See https://loinc.org/license for the full LOINC copyright and license.